EP0664803A1 - Composes n-arylheteroarylalkyle 1-cycloalkyle-imidazole-2-one pour le traitement des maladies circulatoires - Google Patents

Composes n-arylheteroarylalkyle 1-cycloalkyle-imidazole-2-one pour le traitement des maladies circulatoires

Info

Publication number
EP0664803A1
EP0664803A1 EP93915307A EP93915307A EP0664803A1 EP 0664803 A1 EP0664803 A1 EP 0664803A1 EP 93915307 A EP93915307 A EP 93915307A EP 93915307 A EP93915307 A EP 93915307A EP 0664803 A1 EP0664803 A1 EP 0664803A1
Authority
EP
European Patent Office
Prior art keywords
methyl
butyl
phenyl
pyridinyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93915307A
Other languages
German (de)
English (en)
Inventor
David B. Reitz
Robert E. Manning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of EP0664803A1 publication Critical patent/EP0664803A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un groupe de composés N-arylhétéroarylalkyle 1-cycloalkyle-imidazole-2-one, utilisés dans le traitement des maladies circulatoires telles que l'hypertension et les défauts cardiaques congestifs, est décrit. Les composés ayant un intérêt particulier sont les antagonistes de l'angiotensine II selon la formule (A), dans laquelle A est sélectionné parmi: (a), (b), (c), (d), (e) et (f), dans lesquelles chaque R?1, R2 et R3¿ est indépendamment sélectionné dans les composés hydrides, alkyle, alkoxy, halo, hydroxy, carboxyle, alkoxy carbonyle, formyle et acétyle; dans lesquelles R7 représente un hydrido; dans lesquelles R8 représente un alkyle; dans lesquelles R9 représente un groupe acide sélectionné parmi COOH et (g) ou une forme stéréo-isomère ou tautomère de ces composés ou un sel pharmaceutiquement acceptable de ces composés.
EP93915307A 1992-10-13 1993-06-16 Composes n-arylheteroarylalkyle 1-cycloalkyle-imidazole-2-one pour le traitement des maladies circulatoires Withdrawn EP0664803A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95957592A 1992-10-13 1992-10-13
US959575 1992-10-13
PCT/US1993/005601 WO1994008989A1 (fr) 1992-10-13 1993-06-16 Composes n-arylheteroarylalkyle 1-cycloalkyle-imidazole-2-one pour le traitement des maladies circulatoires

Publications (1)

Publication Number Publication Date
EP0664803A1 true EP0664803A1 (fr) 1995-08-02

Family

ID=25502163

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93915307A Withdrawn EP0664803A1 (fr) 1992-10-13 1993-06-16 Composes n-arylheteroarylalkyle 1-cycloalkyle-imidazole-2-one pour le traitement des maladies circulatoires

Country Status (5)

Country Link
EP (1) EP0664803A1 (fr)
JP (1) JPH08502285A (fr)
AU (1) AU4533693A (fr)
CA (1) CA2143192A1 (fr)
WO (1) WO1994008989A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087634A (en) * 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5164403A (en) * 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9408989A1 *

Also Published As

Publication number Publication date
JPH08502285A (ja) 1996-03-12
AU4533693A (en) 1994-05-09
CA2143192A1 (fr) 1994-04-28
WO1994008989A1 (fr) 1994-04-28

Similar Documents

Publication Publication Date Title
US5451592A (en) Method of using N-arylheteroarylalkyl 1-heteroaryl-imidazol-2-one compounds for treatment of a glaucoma disorder
US5087634A (en) N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US6090828A (en) 5-aryleheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
US5187271A (en) N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders
EP0508445B1 (fr) Composés de 1H-1,2,4-triazole 1-Arylhétéroarylalkyl substitués dans le traitement de troubles circulatoires
US6858636B2 (en) 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders
US5451597A (en) Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
US6492397B1 (en) N-arylheteroarylalkyl imidazol-2-one compounds for treatment of arteriosclerosis
EP0664802B1 (fr) Composes n-arylheteroarylalkyle 1-phenyle-imidazole-2-ones pour le traitement des maladies circulatoires
WO1994008989A1 (fr) Composes n-arylheteroarylalkyle 1-cycloalkyle-imidazole-2-one pour le traitement des maladies circulatoires
US5238952A (en) N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5229406A (en) 1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL SE

17Q First examination report despatched

Effective date: 19971104

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000215